KidneyIntelX.dkd
Diabetic kidney disease (DKD) risk assessment
Key Facts
About Renalytix
Renalytix is a leader in applying artificial intelligence and machine learning to kidney disease diagnostics, with a mission to enable early-stage prediction and risk stratification. Its core technology platform integrates diverse data inputs—including electronic health records, validated biomarkers, and genetic information—to generate actionable clinical insights. The company's primary commercial focus is its KidneyIntelX test, which has received FDA De Novo marketing authorization for specific patient populations and is navigating the U.S. healthcare reimbursement landscape. Renalytix faces significant challenges, including commercialization execution, securing broad insurance coverage, and a constrained financial position, but its AI-driven approach represents a novel strategy in the chronic kidney disease market.
View full company profile